LAV Asset Management (Hong Kong) Limited - Net Worth and Insider Trading
LAV Asset Management (Hong Kong) Limited Net Worth
The estimated net worth of LAV Asset Management (Hong Kong) Limited is at least $398 Million dollars as of 2025-06-09. LAV Asset Management (Hong Kong) Limited is the 2102 Investment manager of ImmuneOnco Biopharmaceuticals (Shanghai) Inc and owns about 27,721,575 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) stock worth over $398 Million. Details can be seen in LAV Asset Management (Hong Kong) Limited's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that LAV Asset Management (Hong Kong) Limited has not made any transactions after 2023-09-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of LAV Asset Management (Hong Kong) Limited
LAV Asset Management (Hong Kong) Limited Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, LAV Asset Management (Hong Kong) Limited owns 1 companies in total, including ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) .
Insider Ownership Summary of LAV Asset Management (Hong Kong) Limited
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| HKSE:01541 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc | 2023-09-05 | 2102 Investment manager |
LAV Asset Management (Hong Kong) Limited Latest Holdings Summary
LAV Asset Management (Hong Kong) Limited currently owns a total of 1 stock. LAV Asset Management (Hong Kong) Limited owns 27,721,575 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) as of September 5, 2023, with a value of $398 Million.
Latest Holdings of LAV Asset Management (Hong Kong) Limited
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HKSE:01541 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc | 2023-09-05 | 27,721,575 | 14.34 | 397,527,386 |
Holding Weightings of LAV Asset Management (Hong Kong) Limited
LAV Asset Management (Hong Kong) Limited Form 4 Trading Tracker
According to the SEC Form 4 filings, LAV Asset Management (Hong Kong) Limited has made a total of 1 transactions in ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in ImmuneOnco Biopharmaceuticals (Shanghai) Inc is the sale of 27,721,575 shares on September 5, 2023, which brought LAV Asset Management (Hong Kong) Limited around $0.
Insider Trading History of LAV Asset Management (Hong Kong) Limited
- 1
LAV Asset Management (Hong Kong) Limited Trading Performance
LAV Asset Management (Hong Kong) Limited Ownership Network
Ownership Network List of LAV Asset Management (Hong Kong) Limited
Ownership Network Relation of LAV Asset Management (Hong Kong) Limited
LAV Asset Management (Hong Kong) Limited Owned Company Details
What does ImmuneOnco Biopharmaceuticals (Shanghai) Inc do?
Who are the key executives at ImmuneOnco Biopharmaceuticals (Shanghai) Inc?
LAV Asset Management (Hong Kong) Limited is the 2102 Investment manager of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Other key executives at ImmuneOnco Biopharmaceuticals (Shanghai) Inc include 2201 Interest of corporation controlled by you jia xing han ning qi ye guan li you xian gong si , 2501 Other Tian Wenzhi , and 2201 Interest of corporation controlled by you Yu Xiaoyong .
ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) Insider Trades Summary
Over the past 18 months, LAV Asset Management (Hong Kong) Limited made no insider transaction in ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541). Other recent insider transactions involving ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) include a net purchase of 150,000 shares made by Tian Wenzhi , a net sale of 3,165,000 shares made by shang hai zhang ke ling yi sheng fan chuang ye tou zi zhong xin you xian he huo , and a net sale of 0 shares made by Yu Xiaoyong .
In summary, during the past 3 months, insiders sold 0 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) in total and bought 150,000 shares, with a net purchase of 150,000 shares. During the past 18 months, 3,165,000 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) were sold and 150,000 shares were bought by its insiders, resulting in a net sale of 3,015,000 shares.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541)'s detailed insider trading history can be found in Insider Trading Tracker table.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Insider Transactions
LAV Asset Management (Hong Kong) Limited Mailing Address
Above is the net worth, insider trading, and ownership report for LAV Asset Management (Hong Kong) Limited. Currently GuruFocus does not have mailing address information for LAV Asset Management (Hong Kong) Limited.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
